Comprehensive Complication Index in the Classification of Complications of Percutaneous Nephrolithotomy

NCT ID: NCT05351632

Last Updated: 2022-04-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

644 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-01

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Postoperative complications should be reported systematically, objectively and reproducibly. The Clavien-Dindo Classification (CDC), first described in 2004, is the most popular classification system still in use today for assessing perioperative morbidity and mortality. In 2018, the European Association of Urology (EAU) validated this classification, which was originally defined for general surgery operations, for urological operations as well. There are aspects of the CDC that can be critical and weak. The CDC's main weakness is that in the vast majority of studies it only considers the most serious complications. Minor complications are often overlooked and the overall complication burden is therefore underestimated. Because of this vulnerability, it is difficult to compare complications from different patients. For example, it cannot be determined whether a patient with two Grade I complications has higher postoperative morbidity than a patient with one Grade II complication. To address these limitations, the Comprehensive Complications Index (CCI) was defined in 2013 as a new and more comprehensive scoring system for surgical complications.

The CCI is essentially an index based on the CDC, but sums all postoperative complications by severity and scores them on an interval scale. It is scored from 0 (no complications) to 100 (patient's death) for each patient.

CCI in Urology Practice; Validated for Radical Cystectomy, Radical Prostatectomy, Radical Nephroureterectomy, Partial Nephrectomy.

In recent years, validation studies of this index have been carried out in endourological surgeries.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Percutaneous kidney stone surgery (PNL) will be performed due to kidney stones, and 644 patients will be included in the study according to the power analysis\*. Demographic data of the patients, stone characteristics and data related to stone burden, data related to the operation will be noted by looking at the hospital files. Patients who have undergone surgery can be discharged after an average of 3 days and can be called for routine control after an average of 2 months. All complications developed during the inpatient follow-up and any complications developed during the control period will be noted using the patient's file information. Then, all these complications that are detected to develop will be scored separately using the CCI and CDC complication scales.

1. Using the free online tool www.assessurgery.com, the Comprehensive Complications Index (CCI) score for the total burden of complications will be calculated for each patient.
2. Each patient's most major complication will be determined and graded according to the Clavien-Dindo (CDC) classification (as described below).

Grade I: Any deviation from the normal postoperative course requiring only the following drugs: antiemetics, antipyretics, diuretics Grade II: Pharmacological therapy (with drugs not necessary for CDC I complications), blood transfusion, total parenteral nutrition Grade IIIa: Surgical, endoscopic or radiological intervention not under general anesthesia Grade IIIb: Surgical, endoscopic or radiological intervention under general anesthesia Grade IVa: single organ dysfunction requiring intensive care unit management Grade IVb: multiple organ dysfunction requiring intensive care unit management Grade V: Death

All the data obtained, CCI and CDC, will be compared among themselves in terms of reliability, demographic data obtained from the pre-operative file data, stone characteristics and data related to the operation will be compared, as well as their relationship with the length of hospital stay.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complications, Postoperative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To have a medical indication for percutaneous kidney stone surgery
* To have given consent to participate in the study
* To be18 years of age or older

Exclusion Criteria

* To be under the age of 18
* Not to have given consent to participate in the study
* Not to have a medical indication for percutaneous kidney stone surgery
* To Have an orthopedic disorder that prevents him from undergoing percutaneous kidney stone surgery
* To have a hematological disorder that prevents percutaneous kidney stone surgery
* To have a malignancy that prevents percutaneous kidney stone surgery
* To have a serious cardiac and respiratory comorbidities that prevent percutaneous kidney stone surgery
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zonguldak Bulent Ecevit University

OTHER

Sponsor Role collaborator

Ankara University

OTHER

Sponsor Role collaborator

Inonu University

OTHER

Sponsor Role collaborator

Istanbul University

OTHER

Sponsor Role collaborator

Acibadem University

OTHER

Sponsor Role collaborator

Eskisehir Osmangazi University

OTHER

Sponsor Role collaborator

Başakşehir Çam & Sakura City Hospital

OTHER_GOV

Sponsor Role collaborator

Koç University

OTHER

Sponsor Role collaborator

Izmir Metropolitan Municipality Esrefpasa Hospital

UNKNOWN

Sponsor Role collaborator

Alanya Alaaddin Keykubat University

OTHER

Sponsor Role collaborator

Cukurova University

OTHER

Sponsor Role collaborator

Ondokuz Mayıs University

OTHER

Sponsor Role collaborator

Dokuz Eylul University

OTHER

Sponsor Role collaborator

Samsun Education and Research Hospital

OTHER

Sponsor Role collaborator

Gazi University

OTHER

Sponsor Role collaborator

Hacettepe University

OTHER

Sponsor Role collaborator

Abant Izzet Baysal University

OTHER

Sponsor Role collaborator

Ankara Training and Research Hospital

OTHER

Sponsor Role collaborator

Hitit University

OTHER

Sponsor Role collaborator

Baskent University

OTHER

Sponsor Role collaborator

Marmara University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yiloren Tanidir

Associ.Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Reha GİRGİN, Assist.Prof.

Role: STUDY_DIRECTOR

Zonguldak Bulent Ecevit University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zonguldak Bülent Ecevit University, school of medicine

Zonguldak, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Reha GİRGİN, Assist.Prof.

Role: CONTACT

05378865912

Yilören TANIDIR, Associ.Prof.

Role: CONTACT

05325694275

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Reha Girgin, Assist.Prof.

Role: primary

05378865912

Yilören TANIDIR, Associ.Prof.

Role: backup

05325694275

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022/06-7

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Changes Post Percutaneous Nephrolithotomy
NCT06185387 NOT_YET_RECRUITING